NCT06221462 (PRIORITY) is a Phase 2 clinical trial of Sintilimab in Carcinoma, Non-Small-Cell Lung, sponsored by Ningbo No.2 Hospital.

Who is sponsoring NCT06221462?

NCT06221462 is sponsored by Ningbo No.2 Hospital.

What drugs are being tested in NCT06221462?

Interventions in NCT06221462: Sintilimab, Anlotinib.

What condition does NCT06221462 study?

NCT06221462 studies Carcinoma, Non-Small-Cell Lung.

Is NCT06221462 still recruiting?

NCT06221462 is currently not yet recruiting. Last updated 25 January 2024.

Last reviewed 2024-01-25 · How we verify

NCT06221462: PRIORITY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

Not yet recruiting Phase 2 Last updated 25 January 2024

What this trial tests

Phase 2 trial testing Sintilimab in Carcinoma, Non-Small-Cell Lung in 30 participants. Not yet recruiting.

Timeline

1 February 2024

Primary endpoint
28 February 2025

1 February 2030

Quick facts

Lead sponsor	Ningbo No.2 Hospital
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 February 2024
Primary completion	28 February 2025
Estimated completion	1 February 2030

Drugs / interventions tested

Sintilimab — full drug profile →
Anlotinib — full drug profile →

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →

Sponsor

Ningbo No.2 Hospital

Who can join

Adults 18 to 75, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective single-center, open-label, phase II study evaluating the efficacy of sintilimab plus anlotinib as a neoadjuvant regimen in the treatment of IB-IIIB resectable non-small cell lung cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-Immunotherapy.
Ohara S, Suda K, Tsutani Y. · · 2025 · cited 3× · PMID 40940723 · DOI 10.3390/cells14171312
Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery.
Jeon H, Gor R, D'Aiello A, Stiles B, et al · · 2024 · cited 1× · PMID 38957347 · DOI 10.3389/pore.2024.1611817

Verify or expand the search:

Other trials of Sintilimab

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Other Ningbo No.2 Hospital trials

Trials by the same sponsor.

NCT07378124 — LLL vs. SDL for LBBP: A Non-inferiority RCT · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06221462 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ningbo No.2 Hospital
Last refreshed: 25 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06221462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing